Remove 2027 Remove FDA Remove Sales
article thumbnail

Treatment options for Crohn’s disease expand after Rinvoq approval

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition. The FDA nod means Rinvoq is now approved for seven indications in gastroenterology, rheumatology and dermatology.

article thumbnail

Potential blockbuster drugs to watch in 2023

European Pharmaceutical Review

Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. They have accounted for over 25 percent of Food and Drug Administration (FDA) approvals for the last seven years, the report found.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Provention finally gets FDA nod for type 1 diabetes drug teplizumab

pharmaphorum

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. It is now in line for a $35 million equity investment by Sanofi following FDA approval.

FDA 52
article thumbnail

Merck obtains favourable US court ruling on sitagliptin patent lawsuit

Pharmaceutical Technology

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Viatris is seeking approval from the US Food and Drug Administration (FDA) to market Januvia and Janumet’s generic versions in the country. Merck has also permitted the sale of generic versions of Janumet XR to the market in July 2026 or before.

article thumbnail

What A Field Clinical Engineer In Neuromodulation Sales Does With Blake Williams

Evolve Your Success

He provides a fascinating glimpse into what it takes to excel in the field of medical device sales, emphasizing the importance of authenticity and passion. Blake has a unique case because he was a cardiac, cath lab, critical care, and surgery nurse who got into medical sales. People come from sales, clinical, and engineers.

article thumbnail

Chasing rivals, AbbVie files migraine prevention drug atogepant in EU

pharmaphorum

The market research group recently predicted Vydura and atogepant will achieve sales of $35 million and $57 million, respectively, by 2030 in the five major European markets of France, Germany, Italy, Spain, and the UK. GlobalData has said it expects Qulipta to get approval for chronic migraine prevention in 2023, helping it to sales of $1.2

Sales 52
article thumbnail

Lilly holds off on tirzepatide filing in obesity, waiting for second trial

pharmaphorum

On the plus side, the time that tirzepatide will stay under review at the FDA has just got shorter, as the FDA has granted the drug fast-track review that means it should make a decision within six months of the filing being completed. billion in 2025 sales.

Sales 52